An Exploratory Phase 2, Randomised, Double-blind, Placebo-controlled, and Open-label Active Comparator Study to Evaluate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects with Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Cotadutide (Primary) ; Liraglutide
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors AstraZeneca; MedImmune
- 16 Oct 2019 Planned number of patients changed from 44 to 50.
- 24 Jul 2019 Planned number of patients changed from 51 to 44.
- 05 Jul 2019 Planned number of patients changed from 44 to 51.